Svitlana Garbuzova-Davis

TL;DR: Cord blood transfusion into the systemic circulation of G93A mice delayed disease progression at least 2-3 weeks and increased lifespan of diseased mice, indicating that cord blood may have therapeutic potential in this noninvasive cell-based treatment of ALS.

TL;DR: It is shown that removal of the spleen significantly reduces neurodegeneration after ischemic insult, and the peripheral immune response as mediated by theSpleen is a major contributor to the inflammation that enhances neurodegneration after stroke.

TL;DR: Results suggest that the BSCB is compromised in areas of motor neuron degeneration in ALS mice at both early and late stages of the disease.

TL;DR: Results show that disruption of BBB and BSCB was evident in areas of motor neuron degeneration in G93A mice at both early and late stages of disease.

TL;DR: Microvascular barrier abnormalities determined in gray and white matter of the medulla, cervical, and lumbar spinal cord of SALS patients are novel findings that may have implications for disease pathogenesis and progression, as well as for uncovering novel therapeutic targets.